{
  "pfizerFacts": [
    {
      "description": "Patriarch of Generation G-1 born to Anthony F. and Mary J. (Johnson) Wawrzyniak",
      "title": "Mark M. Wawrzyniak",
      "date": "1960/04/15"
    },
    {
      "description": "First-born of current generation born to Mark M. and Linda M. (King) Wawrzyniak",
      "title": "Elizabeth M. Wawrzyniak",
      "date": "1984/10/03"
    },
    {
      "description": "Twins and last of current generation born to Mark M. and Linda M. (King) Wawrzyniak",
      "title": "Sara J. and Thomas M. Wawrzyniak"
      "date": "1994/10/19"
    },
    {
      "description": "Joe and Sarah expecting a little girl, first member of the next generation of Wawrzyniaks in this branch of the family.",
      "title": "Baby Wawrzyniak due",
      "date": "2021/06/28"
    }
  ],
  "pfizerTimeline": [
    {
      "description": "The previous generation, parents to Gen0",
      "title": "Generation G-1",
      "start": "1960/04/15",
      "end": "1984/10/02"
    },
    {
      "description": "The current generation",
      "title": "Generation G0",
      "start": "1984/10/03",
      "end": "2021/06/27",
      "color": "#00a950"
    },
    {
      "description": "A new generation of Wawrzyniaks begins.",
      "title": "Generation G+1",
      "start": "2021/06/28",
      "color": "#00a950"
    }
  ],
  "otherVaccines": [
    {
      "description": "Moderna (along with Pfizer) uses a new vaccine approach involving messenger RNA",
      "title": "Moderna trials start",
      "date": "2020/07/27"
    },
    {
      "description": "Submitted for review",
      "title": "Moderna Review",
      "date": "2020/11/30"
    },
    {
      "description": "Dosage - 2 doses, 4 weeks apart",
      "title": "Moderna US Approval",
      "date": "2020/12/18"
    },
    {
      "description": "The vaccine is being developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson",
      "title": "Johnson and Johnson trials start",
      "date": "2020/09/07"
    },
    {
      "description": "Trial shows 66% efficacy",
      "title": "Johnson and Johnson Review",
      "date": "2021/01/29"
    },
    {
      "description": "Dosage - 1 dose",
      "title": "Johnson and Johnson US Approval",
      "date": "2021/02/27"
    },
    {
      "description": "Vaccine developed by a small biotech firm in US",
      "title": "Novavax trials start",
      "date": "2020/09/28"
    },
    {
      "description": "Trial shows about 90% efficacy",
      "title": "Novavax Review",
      "date": "2021/01/28"
    },
    {
      "description": "US pauses J&J vaccine over clot reports",
      "title": "Johnson and Johnson vaccine paused",
      "date": "2021/04/13"
    }
  ]
 }
